April 2025 | Volume 24 | Issue 4 | 413 | Copyright April 2025 Published online March 7, 2025 doi:10.36849/JDD.8605 Sophia Daniel BS a,b , Stephanie Waggett BS a,c , Elliott Lyles BS a , Pelin Sagut MD a,d , Parisa Shamaei Zadeh MSPH b , Anthony Marcelletti BHS b , Carol Stegura ME c , Lara Wine Lee MD PhD d a College of Graduate Studies, Medical University of South Carolina, Charleston, SC b College of Medicine, University of Kentucky, Lexington, KY c College of Medicine, Medical University of South Carolina, Charleston, SC d Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC Abstract Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss
Before increasing the dosage, use the existing dose for at least 4 weeks
Finally, RWS consistently reported better cardiovascular and renal outcomes of users of GLP-1RAs as compared to DPP-4 inhibitors users, and highlights the needs for further RWS comparing GLP-1RAs and SGLT-2i (and their combinations) on cardiovascular outcomes, that should eventually be confirmed by dedicated RCTs
Close monitoring of the acid-base status is required in debilitated patients or severely ill patients in whom respiratory acidosis or metabolic acidosis may occur (e.g., cardiopulmonary disease or uncontrolled diabetes)
90471-79-7, with high quality and used in food, cosmetics, and dietary supplements
If the pharmacy can not provide a lot number, or if the number comes back as unverified, do not use the product
